KBC Group’s Recursion Pharmaceuticals RXRX Stock Holding History

KBC Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$112K	Buy	27,232 +14,925	+121%	+$50.6K	﹤0.01%	1315
2026 Q2	$45K	Hold	12,307	–	–	﹤0.01%	1737
2026 Q1	$38K	Hold	12,307	–	–	﹤0.01%	1744
2025 Q4	$50K	Hold	12,307	–	–	﹤0.01%	1643
2025 Q3	$60K	Hold	12,307	–	–	﹤0.01%	1580
2025 Q2	$62K	Hold	12,307	–	–	﹤0.01%	1486
2025 Q1	$65K	Hold	12,307	–	–	﹤0.01%	1711
2024 Q4	$83K	Buy	12,307 +4,705	+62%	+$31.6K	﹤0.01%	1665
2024 Q3	$50K	Buy	7,602 +3,377	+80%	+$24.2K	﹤0.01%	1710
2024 Q2	$32K	Hold	4,225	–	–	﹤0.01%	1807
2024 Q1	$42K	Hold	4,225	–	–	﹤0.01%	1644
2023 Q4	$42K	Hold	4,225	–	–	﹤0.01%	1651
2023 Q3	$32K	Buy	+4,225	New	+$42.1K	﹤0.01%	1759

Other funds holding RXRX

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Values First Advisors Gray, Tennessee $213M AUM 20.51% 1-Year Est. Return

KBC Group's RXRX Position: Q3 2026 in Review

KBC Group increased its Recursion Pharmaceuticals (RXRX) stake by 121% in Q3 2026, buying an estimated $50.6K and bringing the position to 27,232 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #1315.

KBC Group first reported a position in RXRX in Q3 2023 and has held it in 13 quarters since. 83 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

KBC Group held 27,232 shares of Recursion Pharmaceuticals worth $112K as of Q3 2026.
KBC Group bought 14,925 Recursion Pharmaceuticals shares in Q3 2026, an estimated $50.6K.
Recursion Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1315 holding.
KBC Group first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 13 quarters since.
83 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.